

Therapeutic Class Overview

Opioids, Long Acting

INTRODUCTION

- Pain originates from somatic or visceral structures. Somatic pain is localized and typically results from injury or disease of the skin, musculoskeletal structures, and joints. Visceral pain arises from internal organ dysfunction or from functional pathology.
- Pain can be acute or chronic. Acute pain often results from injury or inflammation and may have a survival role and assist in the healing process by minimizing re-injury. In contrast, chronic pain, often defined as pain persisting for over three to six months, may be considered a disease in that it serves no useful purpose (*Cohen and Raja 2020*).
 - It is estimated that approximately 20.4% of adults in the United States (US) have chronic pain with a prevalence of 7.4% high-impact chronic pain (ie, pain that limits life or work activities on most days) (*Zelaya et al 2019*).
- Pain may be classified as nociceptive, neuropathic, nociplastic, or mixed (*Cohen and Raja 2020*).
 - Nociceptive pain, including cancer pain, results from an injury or disease affecting somatic structures such as skin, muscle, tendons and ligaments, bone, and joints. It is typically treated with nonopioid analgesics or opioids.
 - Neuropathic pain results from disease or injury to the peripheral or central nervous systems (CNS) and is less responsive to opioids. It is often treated with adjuvant drugs such as antidepressants and antiepileptics. Opioids are recommended as second- or third-line agents.
 - Nociplastic pain is pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain. These conditions include pain states such as fibromyalgia, irritable bowel syndrome, etc., and were formerly known as “functional pain syndromes”.
 - Mixed pain is pain that contains significant portions of both neuropathic and nociceptive pain.
- Several pharmacologic and nonpharmacologic options are currently available for the management of pain. Treatment options include pharmacologic treatment, physical medicine, behavioral medicine, neuromodulation, interventional, and surgical approaches. Pharmacologic therapy should not be the sole focus of pain treatment; however, it is the most widely utilized option (*Cohen and Raja 2020*).
 - Major pharmacologic categories used in the management of pain include non-opioid analgesics, tramadol, opioid analgesics (full and partial agonists), alpha-2 (α_2) adrenergic agonists, antidepressants, anticonvulsants, muscle relaxants, N-methyl-d-aspartate (NMDA) receptor antagonists, and topical analgesics. Opioids are available in both short-acting and long-acting or sustained release formulations (*Cohen and Raja 2020*).
 - Combining different types of treatments, including multiple types of analgesics, may provide an additive analgesic effect without increasing adverse effects (*Cohen and Raja 2020, The Medical Letter 2013*).
- It is important that patients receive appropriate pain treatment with careful consideration of the benefits and risks of treatment options. The use of opioid analgesics presents serious risks, including overdose and opioid use disorder. From 1999 to 2014, there were more than 165,000 deaths due to opioid analgesic overdoses in the U.S. (*Dowell et al 2016*).
- The long-acting opioids have gained increasing attention regarding overuse, abuse, and diversion. Some manufacturers have addressed concerns about abuse and misuse by developing new formulations designed to help discourage the improper use of opioid medications.
 - In January 2013, the Food and Drug Administration (FDA) released draft guidance for industry regarding abuse deterrent opioids. This document was finalized in April 2015. The guidance explained the FDA’s current direction regarding studies conducted to demonstrate that a given formulation has abuse deterrent properties. The guidance also made recommendations about how those studies should be performed and evaluated (*FDA Industry Guidance 2015*). The 2015 guidance did not address generic opioids. Subsequently in November 2017, the FDA issued a final guidance to support industry in the development of generic versions of abuse-deterrent opioids (*FDA Industry Guidance 2017*).
 - In 2013, reformulated OxyContin (oxycodone) became the first long-acting opioid to be approved with labeling describing the product’s abuse deterrent properties consistent with the FDA’s guidance for industry (*Hale et al 2016*).

- Since the approval of reformulated OxyContin, other long-acting opioids have been approved with abuse deterrent labeling including Hysingla extended-release (ER) and Xtampza ER (*Drugs@FDA 2021, Hale et al 2016*).
- A number of federal agencies have implemented measures to combat drug abuse and misuse. The Centers for Medicare & Medicaid Services (CMS) has issued guidance in an effort to improve drug utilization review controls in Part D prescription plans. The U.S. Office of Disease Prevention and Health Promotion offers an interactive training tool, “Pathways to Safer Opioid Use,” which teaches healthcare providers how to implement opioid-related recommendations from the adverse events action plan. Additionally, the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), has a number of studies and initiatives to educate providers and patients about opioid addiction and treatment. On July 13, 2017, the National Academies of Science, Engineering, and Medicine (NASAM) also released a consensus report, commissioned by the FDA, which outlined the state of the science regarding prescription opioid abuse and misuse, as well as the evolving role that opioids play in pain management (*CMS Web site 2021, NASAM 2017, NIDA 2015, Office of Disease Prevention and Health Promotion 2020*).
- In December 2018, the U.S. Department of Health & Human Services (HHS) recommended prescribing or co-prescribing naloxone to all patients who are at risk for opioid overdose, including: patients receiving opioids at a dosage of 50 milligram morphine equivalents (MME) per day or greater; patients with respiratory conditions who are prescribed opioids; patients who have been prescribed benzodiazepines along with opioids; and patients prescribed opioids who have a non-opioid substance use disorder, report excessive alcohol use, or have a mental health disorder (*HHS 2018*).
- In March 2016, the Centers for Disease Control and Prevention (CDC) issued a guideline for prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses when to initiate or continue opioids for chronic pain; opioid selection, dosage, duration, follow-up, and discontinuation; and assessing risks and addressing harms of opioid use. The guideline encourages prescribers to follow best practices for responsible opioid prescribing due to the risks of opioid use (*Dowell et al 2016*).
- Methadone is FDA-approved for detoxification and maintenance treatment of opioid addiction.
 - Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority. Certified treatment programs shall dispense and use methadone in oral form only and according to the treatment requirements stipulated in the Federal Opioid Treatment Standards (42 CFR 8.12) (*Prescribing information: Dolophine 2019, methadone oral solution 2020, Methadose 2020*).
- Included in this review are the long-acting opioids, which are primarily utilized in the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Long-acting opioids are available in a variety of different dosage forms, and currently several agents are available generically (*Drugs@FDA 2021*).
 - All of the long-acting opioids are classified as Schedule II controlled substances by the FDA, with the exception of transdermal and buccal buprenorphine, a partial opioid agonist, which is a Schedule III controlled substance.
- Since some agents are available under multiple brand names, many tables in this review are arranged by generic name.
- Medispan class: Opioid Agonists

Table 1. Medications Included Within Class Review

Drug	Generic Availability
Kadian [‡] , MS Contin (morphine sulfate)	✓
Belbuca [†] , Butrans (buprenorphine)	✓
Dolophine [‡] , Methadose (methadone)	✓
Duragesic (fentanyl)	✓
Exalgo [‡] (hydromorphone)	✓
Hysingla ER ^{*†} , Zohydro ER [§] (hydrocodone bitartrate)	✓
levorphanol	✓
Nucynta ER (tapentadol)	-
Opana ER (oxymorphone)	✓
OxyContin ^{*¶} , Xtampza ER ^{*†} (oxycodone)	✓

*Approved as an abuse deterrent (AD) formulation, which is consistent with the FDA’s 2015 guidance for industry, *Abuse-Deterrent Opioids – Evaluation and Labeling*.



† Brand product only; generic is not available

‡ Brand product is no longer marketed; product is only available generically.

§ In February 2015, a new formulation of Zohydro ER was FDA-approved with AD properties; however, it has not been deemed to meet the FDA requirements for labeling as an AD opioid.

|| Generic products of the pre-reformulated Opana ER are available. The branded versions of Opana ER (pre- and post-reformulation) are no longer available on the market.

¶ OxyContin had various patents extending out to 2027. Patent litigation on OxyContin reached an agreement between manufacturers. In late 2014, a number of generic products launched.

(Drugs@FDA 2021, FDA Industry Guidance 2015, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2021)

INDICATIONS

Table 2. Food and Drug Administration Approved Indications

Indications	buprenorphine	fentanyl	hydrocodone	hydromorphone	levorphanol	methadone	morphine	oxycodone	oxymorphone	tapentadol
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in adults.	✓		✓			✓*	✓	✓	✓	✓
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in opioid-tolerant pediatric patients ≥ 11 years of age who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent.								✓†		
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.					✓					
Management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.		✓‡		✓‡						
Management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate										✓
Detoxification treatment of opioid addiction (heroin or other morphine-like drugs)						✓				
Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with social and medical services						✓				
<i>Limitations of Use:</i> Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release (ER) opioid formulations, reserve this agent for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
<i>Limitations of Use:</i> Not indicated as an as-needed (prn) analgesic.	✓	✓	✓	✓		✓	✓	✓	✓	✓

*Methadone tablets and oral solution only

†OxyContin only

‡Patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.

(Prescribing information: Belbuca 2020, Butrans 2019, Dolophine 2019, Duragesic 2019, Exalgo 2020, hydromorphone extended-release 2020, Hysingla ER 2019, Kadian 2019, levorphanol 2020, methadone oral solution 2020, Methadose 2020, morphine sulfate extended release 2021, MS Contin 2019, Nucynta ER 2019, OxyContin 2020, oxymorphone extended-release 2020, Xtampza ER 2019, Zohydro ER 2019)

- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

CLINICAL EFFICACY SUMMARY

- As a class, the long-acting opioids are a well-established therapy for the treatment of moderate to severe pain. In general, opioids are used for the treatment of non-cancer and cancer pain; however, data establishing their effectiveness in the treatment of neuropathic pain are available. Head-to-head trials of long-acting opioids do exist and for the most part the effectiveness of the individual agents, in terms of pain relief, appears to be similar. Small differences between the agents exist in side effect profiles, and associated improvements in quality of life or sleep domains (*Agarwal et al 2007, Aiyer et al 2017, Allan et al 2001, Allan et al 2005, Bao et al 2016, Bekkering et al 2011, Bruera et al 2004, Buynak et al 2010, Caldwell et al 2002, Caraceni et al 2011, Chou et al 2015, Clark et al 2004, Conaghan et al 2011, Felden et al 2011, Finkel et al 2005, Finnerup et al 2015, Gimbel et al 2003, Gordon et al 2010a, Gordon et al 2010b, Karlsson et al 2009, Hale et al 2007, Hale et al 2010, Katz et al 2010, King et al 2011, Kivitz et al 2006, Langford et al 2006, Melilli et al 2014, Mercadante et al 2010, Mesgarpour et al 2014, Morley et al 2003, Musclow et al 2012, Nicholson et al 2017, Park et al 2011, Pigni et al 2011, Quigley et al 2002, Rauck et al 2014, Schwartz et al 2011, Slatkin et al 2010, Sloan et al 2005, Watson et al 2003, Whittle et al 2011, Wiffen et al 2016, Wild et al 2010*).
- Some systematic reviews and meta-analyses recommend opioids as a potential treatment option for various forms of non-cancer and cancer-related pain; however, other meta-analyses in non-cancer pain have not found a clinically meaningful difference between opioids, other non-opioid pain medications, and placebo. No single opioid is recommended over the others (*Busse et al 2018, Chou et al 2015, Finnerup et al 2015, Mesgarpour et al 2014, Stewart et al 2018*).
 - The Agency for Healthcare Research and Quality (AHRQ) conducted a systematic review (N = 39 studies, 40 publications) of the effectiveness and risks of long-term (>3 months) opioid therapy for chronic pain and included both randomized and observational studies. Findings indicated that three randomized, head-to-head trials of various long-acting opioids found no differences in one-year outcomes related to pain or function. One good-quality case-control study found current opioid use to be associated with increased risk for hip, humerus, or wrist fracture versus non-use (adjusted odds ratio [OR], 1.27; 95% confidence interval [CI], 1.21 to 1.33). The risk was highest with one prescription (OR, 2.7; 95% CI, 2.34 to 3.13) and decreased with higher numbers of prescriptions, with no increased risk with more than 20 cumulative prescriptions. One fair-quality cohort study found that a cumulative opioid supply of at least 180 days over a 3.5-year period was associated with an increased risk for myocardial infarction versus no long-term opioid therapy (adjusted incidence rate ratio, 2.66; 95% CI, 2.3 to 3.08) (*Chou et al 2015*).
 - A systematic review and meta-analysis of 96 randomized controlled trials (RCTs) examined the use of opioids in chronic non-cancer pain. Opioid use was associated with reduced pain compared to placebo (weighted mean difference [WMD], -0.69 cm on a 10-cm visual analog scale; 95% CI, -0.82 to -0.56 cm; $p < 0.001$), as well as improved physical functioning as measured by the 36-item Short Form physical component score (SF-36 PCS; WMD, 2.04 points on a 100-point scale; 95% CI, 1.41 to 2.68 points; $p < 0.001$). However, the minimally important difference (pain, 1 cm; SF-36 PCS, 5 points) was not reached for either parameter. Opioids were also associated with increased vomiting vs placebo (5.9% vs. 2.3%). When opioids were compared to nonsteroidal anti-inflammatory drugs (NSAIDs), similar improvements in pain and physical functioning were observed (pain WMD for opioids vs NSAIDs, -0.60 cm; 95% CI, -1.54 to 0.34; physical functioning WMD for opioids vs NSAIDs, -0.90 points; 95% CI, -2.69 to 0.89) (*Busse et al 2018*). Similarly, another systematic review and meta-analysis of 29 studies found that opioids and other commonly used classes of pain medication produced similar percent reductions in osteoarthritis pain (opioids, 35.4%; oral NSAIDs, 34.3%; topical NSAIDs, 40.9%; acetaminophen, 32.5%; cyclooxygenase-2 [COX-2] inhibitors, 36.9%) (*Stewart et al 2018*).
 - The Special Interest Group on Neuropathic Pain of the International Association for the Study of Pain conducted a systematic review and meta-analysis of randomized, double-blind (DB) studies of oral and topical therapy for neuropathic pain and required a number needed to treat (NNT) for 50% pain relief as the primary measure. For tapentadol ER, the review identified one negative study and one positive enrichment study with a potential bias and a high NNT of 10.2 (95% CI, 5.3 to 185.5) in 67% of the patients responding to the open phase. Thirteen trials were identified with strong opioids, in which oxycodone (10 to 120 mg/day) and morphine (90 to 240 mg/day) were used mainly in peripheral neuropathic pain. The final quality of evidence was moderate. Ten trials were positive with a combined NNT of 4.3 (95% CI, 3.4 to 5.8) and a number needed to harm of 11.7 (95% CI, 8.4 to 19.3). Maximum effectiveness seemed to be associated with 180 mg morphine or equivalent (*Finnerup et al 2015*).
 - Another systematic review evaluated long-acting opioids in the treatment of moderate to severe cancer pain. The review included only DB, RCTs for efficacy assessments; open-label (OL) and controlled observational studies were

allowed for safety assessments. A total of five RCTs and four observational studies met criteria for inclusion. Similar pain intensity improvements were demonstrated for oxycodone ER, oxycodone/naloxone ER, hydromorphone ER, and oxycodone ER. However, the average equivalent dose of oxycodone ER was significantly different from hydromorphone ER. The Morphine ER and hydromorphone ER groups had similar improvements in average cancer pain in the past 24 hours and “current pain in the morning;” however, the “worst pain in the past 24 hours” and “current pain in the evening” were significantly lower in the hydromorphone ER group. The quality of life scores were comparable between oxycodone ER and oxycodone/naloxone ER as well as morphine ER and hydromorphone ER in two trials. The rate of discontinuation due to lack of efficacy was similar among patients treated with morphine ER, hydromorphone ER, oxycodone ER or oxycodone/naloxone ER and ranged from 1.1% (oxycodone/naloxone ER) to 6.5% (hydromorphone ER). The risk of experiencing serious adverse events was comparable in patients treated with morphine ER or hydromorphone ER, morphine ER or fentanyl ER, and morphine ER or oxycodone ER. Overall, the reviewers concluded that there was no difference in efficacy and risk of harms among ER opioids in the treatment of cancer-related pain based on current evidence (*Mesgarpour et al 2014*).

- A pragmatic, 12-month, randomized trial (N = 240) compared opioid vs non-opioid medications on pain-related function, pain intensity, and adverse effects in patients with moderate to severe chronic back pain or hip or knee osteoarthritis pain despite analgesic use (*Krebs et al 2018*).
 - Each intervention had its own prescribing strategy that included multiple medication options in 3 steps. In the opioid group, the first step was immediate-release morphine, oxycodone, or hydrocodone/acetaminophen. For the nonopioid group, the first step was acetaminophen or an NSAID. Medications were changed, added, or adjusted within the assigned treatment group according to individual patient response.
 - Groups did not significantly differ on pain-related function over 12 months (p = 0.58); mean 12-month Brief Pain Inventory (BPI) interference was 3.4 for the opioid group and 3.3 for the nonopioid group (difference, 0.1; 95% CI, -0.5 to 0.7). Pain intensity was significantly better in the nonopioid group over 12 months (p = 0.03); mean 12-month BPI severity was 4.0 for the opioid group and 3.5 for the nonopioid group (difference, 0.5; 95% CI, 0.0 to 1.0). Adverse medication-related symptoms were significantly more common in the opioid group over 12 months (p = 0.03); mean medication-related symptoms at 12 months were 1.8 in the opioid group and 0.9 in the nonopioid group (difference, 0.9; 95% CI, 0.3 to 1.5).
- The efficacy of buprenorphine buccal films was evaluated in three 12-week, DB, placebo-controlled (PC) trials in opioid-naïve and opioid-experienced patients with moderate-to-severe chronic low back pain. In the trials, the DB treatment phase was preceded by an OL dose titration period. Patients were eligible for randomization into the 12-week DB treatment phase if they were able to titrate to a tolerable and effective buprenorphine dose. The primary efficacy variable was the patients’ pain scores (based on a 0 to 10 numeric rating scale). Two of these studies demonstrated efficacy in patients with low back pain. One trial did not show a statistically significant pain reduction for Belbuca compared to placebo, and the results of this trial are not included in the Prescribing Information (*Belbuca Prescribing Information 2020, Gimbel et al 2016, Rauck et al 2016*).
 - In one study of opioid-naïve patients, pain scores increased more in the placebo group vs. the buprenorphine group during the DB phase; mean (standard deviation [SD]) changes from baseline to week 12 were 0.94 (1.85) and 1.59 (2.04) in the buprenorphine and placebo groups, respectively, with a significant between-group difference (-0.67; 95% CI, -1.07 to -0.26; p = 0.0012). A higher proportion of buprenorphine patients (62%) had at least a 30% reduction in pain score from prior to OL titration to study endpoint when compared to patients who received placebo (47%) (*Rauck et al 2016*).
 - In another study, opioid-experienced patients experienced a higher increase in their pain scores in the placebo vs. buprenorphine group after randomization. The difference between groups in the mean change from baseline to week 12 was -0.98 (95% CI, -1.32 to -0.64; p < 0.001). A significantly larger percentage of patients receiving buprenorphine than placebo had pain reductions ≥ 30% and ≥ 50% (p < 0.001 for both) (*Gimbel et al 2016*).

CLINICAL GUIDELINES

- Clinical guidelines do not state a preference for the use of one long-acting opioid over another in moderate to severe pain (*Attal et al 2010, Bril et al 2011, Chou et al 2009, Kolasinski et al 2020, Manchikanti et al 2017, Paice et al 2016, Qaseem 2017, The Medical Letter 2013*). However, opioid rotation is recommended if a patient experiences adverse effects from one agent (*Chou et al 2009*). In addition, methadone safety guidelines from the 2014 American Pain Society recommend buprenorphine as an alternative to methadone for the treatment of opioid addiction in patients with risk factors or known QTc prolongation (*Chou et al 2014*).

- In March 2016, the CDC issued a guideline for prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses when to initiate or continue opioids for chronic pain; opioid selection, dosage, duration, follow-up, and discontinuation; and assessing risk and addressing harms of opioid use. Recommendations in the CDC guideline include the following (*Dowell et al 2016*):
 - Nonpharmacologic and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate (category A, evidence 3).
 - Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety (category A, evidence 4).
 - Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy (category A, evidence 3).
 - When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of ER/long-acting opioids (category A, evidence 4).
 - Clinicians should prescribe opioids at the lowest effective dosage. Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing dosage to ≥ 50 MME/day, and should avoid increasing dosage to ≥ 90 MME/day or carefully justify a decision to titrate dosage to ≥ 90 MME/day (category A, evidence 3).
 - Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be needed (category A, evidence 4).
 - Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids (category A, evidence 4).
 - Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥ 50 MME/day), or concurrent benzodiazepine use, are present (category A, evidence 4).
 - Clinicians should review the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months (category A, evidence 4).
 - When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs (category B, evidence 4).
 - Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible (category A, evidence 3).
 - Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder (category A, evidence 2).

Category of Recommendations:

- Category A: Applies to all persons; most patients should receive the recommended course of action.
- Category B: Individual decision making needed; different choices will be appropriate for different patients. Clinicians help patients arrive at a decision consistent with patient values and preferences and specific clinical situations.

Evidence Type:

- Type 1: RCTs or overwhelming evidence from observational studies.
- Type 2: RCTs with important limitations, or exceptionally strong evidence from observational studies.

- Type 3: Observational studies or RCTs with notable limitations.
- Type 4: Clinical experience and observations, observational studies with important limitations, or RCTs with several major limitations.
- In February 2017, the American College of Physicians published clinical practice guidelines for noninvasive treatments of acute, subacute, and chronic low back pain. The guidelines state that clinicians should only consider opioids as an option in patients who have failed other treatments (e.g., non-pharmacological treatment, NSAIDs, tramadol, duloxetine), only if the potential benefits outweigh the risks for individual patients, and after a discussion of known risks and realistic benefits with patients (Qaseem *et al* 2017).
 - There is moderate-quality evidence that show strong opioids (tapentadol, morphine, hydromorphone, and oxycodone) are associated with a small short-term improvement in pain scores (about 1 point on a pain scale of 0 to 10) and function compared with placebo. There is moderate-quality evidence that show no differences among different long-acting opioids for pain or function, and low-quality evidence shows no clear differences in pain relief between long- and short-acting opioids.
- In February 2017, the American Society of Interventional Pain Physicians (ASIPP) also published new practice guidelines for responsible, safe, and effective prescription opioids for chronic non-cancer pain. Similar to other guidelines, they do not recommend one opioid agent over the others. They do provide the following recommendations and conclusions for long-term opioid therapy (Manchikanti *et al* 2017):
 - Initiate opioid therapy with low dose, short-acting drugs, with appropriate monitoring (Evidence: Level II; Strength of Recommendation: Moderate).
 - Consider up to 40 MME as low dose, 41 to 90 MME as a moderate dose, and greater than 91 MME as high dose (Evidence: Level II; Strength of Recommendation: Moderate).
 - Avoid long-acting opioids for the initiation of opioid therapy (Evidence: Level I; Strength of Recommendation: Strong).
 - Recommend methadone only for use after failure of other opioid therapy and only by clinicians with specific training in its risks and uses, within FDA recommended doses (Evidence: Level I; Strength of Recommendation: Strong).
 - Understand and educate patients of the effectiveness and adverse consequences (Evidence: Level I; Strength of Recommendation: Strong).
 - Similar effectiveness for long-acting and short-acting opioids with increased adverse consequences of long-acting opioids (Evidence: Level I-II; Strength of recommendation: Moderate to strong).
 - Recommend long-acting or high dose opioids only in specific circumstances with severe intractable pain (Evidence: Level I; Strength of Recommendation: Strong).
- The guidelines from the American College of Physicians and the ASIPP state that buprenorphine has lower quality evidence and is a third-line opioid for the treatment of pain (Manchikanti *et al* 2017, Qaseem *et al* 2017). A 2020 American College of Physicians and American Academy of Family Physicians guideline recommended against use of opioids for acute pain from non-low back, musculoskeletal injuries in adults (Grade: conditional recommendation; low-certainty evidence) (Qaseem *et al* 2020). This recommendation was related to the risk of gastrointestinal and neurological adverse events, and risk for prolonged use of opioids associated with prescribing for more than 7 days.
- Guidelines from the Society of Critical Care Medicine do not specifically address the use of long-acting opioids in intensive care unit patients; however, they recommend a multimodal approach to analgesia, using non-opioid medications as adjunctive therapy in order to decrease opioid use and optimize pain control (Devlin *et al* 2018). Similarly, an expert consensus guideline on opioid prescribing in surgical procedures from the American College of Surgeons does not make recommendations on long-acting opioid use in this setting, but recommends the maximization of non-opioid analgesia (ie, ibuprofen). It also provides recommendations on the number of oxycodone 5 mg tablets to prescribe after surgery, depending on the type of surgical procedure performed (Overton *et al* 2018). A guideline from the Orthopaedic Trauma Association provides recommendations for pharmacologic and nonpharmacologic pain management strategies in acute musculoskeletal injury; this guideline recommends avoiding long-acting opioids in the acute setting (Hsu *et al* 2019).

SAFETY SUMMARY

- On July 9, 2012, the FDA approved a Risk Evaluation and Mitigation Strategy (REMS) program for ER and long-acting opioids; on September 18, 2018, this REMS was modified to include all immediate-release opioids as well. This program, known as the Opioid Analgesic REMS program, strongly encourages healthcare providers to complete an

approved training program on opioid analgesics. The goal of the REMS is to ensure that benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse (*FDA REMS 2019*)

- All of the long-acting opioids are classified as Schedule II controlled substances by the FDA, with the exception of buprenorphine buccal and transdermal systems, which are Schedule III controlled substances.
Most long-acting opioids are associated with boxed warnings regarding the potential for abuse and misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, an interaction with alcohol, and accidental ingestion risks. **Because ER products deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of morphine present.**
- Dolophine and methadone products have additional boxed warnings regarding life-threatening QT prolongation. Duragesic, Hysingla ER, OxyContin, Xtampza ER, Zohydro ER, and methadone products also have a boxed warning for an interaction with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers). An additional boxed warning for Duragesic cautions against exposure to heat as it may cause increased fentanyl release.
- Key contraindications across the class include acute or severe bronchial asthma, significant respiratory depression, and known or suspected paralytic ileus.
- There are multiple warnings and precautions with each agent. Key safety concerns associated with the opioid analgesics include respiratory depression, driving and operating machinery, hypotension, interactions with other CNS depressants, neonatal opioid withdrawal syndrome, use in special populations, and use in those with gastrointestinal conditions.
- The frequency of adverse reactions varies to some degree with each agent; however, overall adverse reactions are similar within the class. The most common adverse events in adults include nausea, vomiting, constipation, and somnolence.
- OxyContin is approved in patients aged ≥ 11 years. The most frequent adverse events in pediatric patients were vomiting, nausea, headache, pyrexia, and constipation.
- In March 2016, the FDA issued a drug safety communication warning about several safety issues with opioids and describing new class-wide labeling requirements. The warnings include the following (*FDA Drug Safety Communication 2016a*):
 - Opioids can interact with antidepressants and migraine medications to cause serotonin syndrome.
 - Taking opioids may rarely lead to adrenal insufficiency.
 - Long-term opioid use may be associated with decreased sex hormone levels and symptoms such as reduced interest in sex, impotence, or infertility.
- In August 2016, the FDA announced that it is requiring class-wide changes to drug labeling, including patient information, in order to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and benzodiazepines (*FDA Drug Safety Communication 2016b*).
 - Among the changes, the FDA is requiring boxed warnings and patient-focused Medication Guides for prescription opioid analgesics, opioid-containing cough products, and benzodiazepines – nearly 400 products in total – with information about the serious risks associated with using these medications concomitantly. Risks include extreme sleepiness, respiratory depression, coma, and death.
- On March 14, 2017, the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted 18 to 8, that the benefits of reformulated Opana ER (which did not originally gain the labeling describing potential abuse deterrent properties) no longer outweigh its risks. This vote followed an FDA analysis of epidemiological data that indicated that there was a shift in the pattern of Opana ER abuse from the nasal to the injection route after the product was reformulated (*FDA Advisory Committee 2017*). Following the FDA's official withdrawal request, the manufacturer (Endo) announced the voluntary market withdrawal of reformulated Opana ER.
- On September 20, 2017, the FDA advised clinicians that opioid addiction medications, such as methadone and buprenorphine, should not be withheld from patients receiving concurrent benzodiazepines or other CNS depressants (*FDA Drug Safety Communication 2017*). Even though combination therapy with these agents increases the risk of serious side effects, the harm caused by untreated opioid addiction can outweigh these risks.
- In April 2019, the FDA issued a drug safety communication regarding the risk of serious harm when opioid medications are suddenly discontinued or doses are rapidly decreased in patients who are physically dependent on opioids. Sudden discontinuation or rapid dose reduction may result in serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide. Opioid medications should be tapered gradually according to an individualized schedule if discontinuation or dose reduction is necessary (*FDA Drug Safety Communication 2019*).

- In July 2020, the FDA issued a drug safety communication recommending that healthcare professionals discuss the availability of naloxone with all patients receiving opioid pain relievers and consider prescribing it for patients who are at high risk for overdose when initiating and renewing treatment (*FDA News Release 2020*).
 - Prescribing of naloxone should be considered based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose.
 - Naloxone should also be considered if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.

DOSING AND ADMINISTRATION

- Certain strengths are appropriate only for patients who are considered treatment-experienced. A detailed description is available within the prescribing information for each agent regarding when a patient is considered opioid-tolerant, and which strengths are appropriate in these patients.
- See prescribing information for detailed conversion recommendations as there are no established conversions from other opioid agents. When converting from one agent to another, it is better to underestimate need and monitor for breakthrough pain.
- These medications should not be abruptly discontinued in patients who may be physically dependent on opioids. Rapid discontinuation has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide.

Table 3. Dosing and Administration

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Kadian, MS Contin (morphine sulfate)	Capsules, tablet	Oral	MS Contin: Every 8 to 12 hours Kadian: Once daily	<ul style="list-style-type: none"> • Renal dose adjustment is required. • Hepatic dose adjustment is required.
Butrans, Belbuca* (buprenorphine)	Transdermal system (Butrans) Buccal film (Belbuca)	Topical Oral	Administration every 7 days Every 12 hours	<ul style="list-style-type: none"> • Not evaluated in patients with severe hepatic impairment (Butrans). • The maximum dose is 900 mcg every 12 hours. Do not exceed this dose due to the potential for QTc interval prolongation. If pain is not adequately managed on a 900 mcg dose, consider an alternate analgesic (Belbuca). • For severe hepatic impairment, reduce the starting and incremental dose by half (Belbuca).
Dolophine, Methadose (methadone)	Oral solution, dispersible tablets for oral suspension, tablets	Oral	Every 8 to 12 hours (for management of pain)	<ul style="list-style-type: none"> • Due to the large variability in half-life (eg, 8 to 59 hours), dose adjustments may vary greatly. Dose increases may be no more frequent than every 3 to 5 days; however, some may require up to 12 days. • Due to the metabolism of methadone, patients with liver impairment may be at risk of accumulating methadone after multiple dosing.

Data as of March 23, 2021 PH-U/HI-U/RLP

Page 10 of 15

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Duragesic (fentanyl)	Transdermal system	Topical	Administration every 72 hours (Some patients may not achieve adequate analgesia using this dosing interval and may require systems be applied at 48 hours)	<ul style="list-style-type: none"> Use should be avoided in patients with severe renal impairment; in mild to moderate renal impairment: start with one half of the usual dosage. Use should be avoided in patients with severe hepatic impairment; in mild to moderate hepatic impairment, start with one half of the usual dosage.
Exalgo [†] (hydromorphone)	ER tablets	Oral	Once daily	<ul style="list-style-type: none"> Moderate renal impairment: start 50% of the usual dose. Severe renal impairment: start 25% of the usual dose. Moderate hepatic impairment: start 25% of the usual dose.
Hysingla ER*, Zohydro ER (hydrocodone bitartrate)	ER capsules and tablets	Oral	Hysingla ER: Once daily Zohydro ER: Every 12 hours	<ul style="list-style-type: none"> For severe hepatic impairment, reduce the Hysingla ER dose to 1/2 the usual initial dose and start Zohydro ER at the lowest dose of 10 mg every 12 hours. Hysingla ER: In moderate to severe renal impairment (including end stage renal disease), reduce the initial dose to 1/2 the usual initial dose.
Levorphanol	Tablets	Oral	Every 6 to 8 hours	
Nucynta ER (tapentadol)	ER tablets	Oral	Twice daily	<ul style="list-style-type: none"> Not recommended in patients with severe renal impairment. Not recommended in patients with severe hepatic impairment. In patients with moderate hepatic impairment, initiate at 50 mg every 24 hours and do not exceed 100 mg/day.
Opana ER (oxycodone) [‡]	ER tablets	Oral	Every 12 hours	<ul style="list-style-type: none"> Contraindicated in moderate and severe hepatic impairment.
OxyContin, Xtampza ER* (oxycodone)	ER capsules and tablets	Oral	Every 12 hours	<ul style="list-style-type: none"> In hepatic impairment, initiate dose at 1/3 to 1/2 the recommended initial dose.

*Brand product only; generic is not available

† Brand product discontinued, but generic products are available.

‡ Generic products of the pre-reformulated Opana ER are available. The branded versions of Opana ER (pre- and post-reformulation) are no longer available on the market.

CONCLUSION

- Opioids have been the mainstay of pain treatment for a number of years, and there is well-documented evidence of their effectiveness. Oral morphine is the standard for comparison for all other opioid agents currently available. There are several long-acting opioid agents available, which are FDA-approved for the treatment of moderate to severe pain in patients requiring around-the-clock analgesia (*Cohen and Raja 2020*).
 - Levorphanol is indicated for moderate to severe pain where an opioid analgesic is appropriate; however, the FDA-approved indication does not stipulate that patients require around-the-clock, daily dosing for use.
 - Nucynta ER is the only long-acting agent in this class also indicated for neuropathic pain which requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
 - OxyContin has been FDA-approved as an option in pediatric patients, aged ≥ 11 years, for daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate. Unlike adults, pediatric patients must have responded to a minimum opioid daily dose of ≥ 20 mg oxycodone for 5 consecutive days prior to initiating treatment with OxyContin. Although study efficacy and safety data are not rigorous, OxyContin has been prescribed off-label for years within the pediatric population (*FDA Summary Review [OxyContin] 2015*).
- All of the long-acting opioids are classified as Schedule II controlled substances by the FDA, with the exception of transdermal and buccal buprenorphine, which is a Schedule III controlled substance.
- Since 2013, a number of abuse deterrent formulations have come to the market. Although various manufacturers have introduced formulations with properties to deter misuse potential; there are only a few agents that have completed studies supporting the potential to deter abuse and misuse. The only long-acting opioids that meet all requirements and are currently available include OxyContin (oxycodone hydrochloride extended release), Hysingla ER (hydrocodone bitartrate extended release), and Xtampza ER (oxycodone extended release) (*FDA Industry Guidance 2015*).
- All long-acting opioids are part of the Opioid Analgesic REMS program. In general, all of the long-acting opioids are similar in terms of adverse events, warnings, and contraindications. Methadone-containing products warn of the potential for QTc prolongation and risks associated with an interaction with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) is cited within Duragesic, Hysingla ER, methadone-containing products, OxyContin, Xtampza ER, and Zohydro ER labeling. The main differences among the individual agents and formulations are due to dosing requirements and generic availability.
 - Several generic long-acting opioids exist, including hydromorphone; hydrocodone bitartrate; oxymorphone; levorphanol; fentanyl transdermal systems; methadone tablets, solution, and concentrate; morphine sulfate ER tablets and capsules; and oxycodone.
- Head-to-head trials demonstrate similar efficacy among the agents in the class. Systematic reviews and treatment guidelines from several professional organizations support and recommend opioids as a potential treatment option for various forms of non-cancer and cancer-related pain; however, some meta-analyses in non-cancer pain have not found a clinically meaningful difference between opioids, other non-opioid pain medications, and placebo. No single opioid is recommended over the others (*Busse et al 2018, Chou et al 2015, Finnerup et al 2015, Mesgarpour et al 2014, Stewart et al 2018*).
- Methadone safety guidelines from the 2014 American Pain Society recommend buprenorphine as an alternative to methadone for the treatment of opioid addiction in patients with risk factors or known QTc prolongation (*Chou et al 2014*). Other current clinical guidelines do not state a preference for the use of one long-acting opioid over another for use in moderate to severe pain (*Attal et al 2010, Bril et al 2011, Chou et al 2009, Kolasinski et al 2020, Manchikanti et al 2012, Qaseem et al 2017*). However, opioid rotation is recommended if a patient experiences adverse effects from one agent (*Chou et al 2009*). A guideline from the CDC has been published that addresses the use of chronic pain outside of active cancer treatment, palliative care, and end-of-life care; this guideline emphasizes the use of nonpharmacologic and nonopioid therapies when possible, and notes that clinicians should consider opioid therapy only if the expected benefits for both pain and function are anticipated to outweigh risks to the patient (*Dowell et al 2016*).

REFERENCES

- Agarwal A, Polydefkis M, Block B, et al. Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states. *Pain Medicine*. 2007;8(7):554-562.
- Aiyer R, Gulati A, Gungor S, et al. Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies. *Anesth Analg*. 2018;127(2):529-538. doi: 10.1213/ANE.0000000000002718.
- Allan L, Hays H, Jensen NH, et al. Randomized crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. *BMJ*. 2001;322:1-7.

- Allan L, Richarz U, Simpson K, et al. Transdermal fentanyl vs sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. *Spine*. 2005;30(22):2484-2490.
- Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol*. 2010;17(9):1113-e88.
- Bao YJ, Hou W, Kong XY, et al. Hydromorphone for cancer pain. *Cochrane Database Syst Rev*. 2016;10:CD011108.
- Bekkering GE, Soares-Weiser K, Reid K, et al. Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses. *Curr Med Res Opin*. 2011;27(7):1477-1491.
- Belbuca [package insert], Raleigh, NC: BioDelivery Sciences International Inc.; July 2020.
- Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology*. 2011;76(20):1758-1765.
- Bruera E, Palmer JL, Bosnak S, et al. Methadone vs morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. *J Clin Oncol*. 2004;22(1):185-92.
- Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic non-cancer pain: a systematic review and meta-analysis. *JAMA*. 2018;320(23):2448-2460. doi: 10.1001/jama.2018.18472.
- Butrans [package insert], Stamford, CT: Purdue Pharma L.P.; October 2019.
- Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. *Expert Opin Pharmacother*. 2010 Aug;11(11):1787-804.
- Caldwell JR, Rappaport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open label extension trial. *J Pain Symptom Manage*. 2002;23(4):278-291.
- Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. *Palliat Med*. 2011;25(5):402-409.
- Centers for Medicare & Medicaid Services (CMS). Improving Drug Utilization Review Controls in Part D. Updated February 18, 2021. CMS Web site. <http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/RxUtilization.html>. Accessed February 18, 2021.
- Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *J Pain*. 2014;15(4):321-337.
- Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic non-cancer pain. *J Pain*. 2009;10(2):113-130.
- Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med*. 2015;162(4):276-286.
- Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. *Curr Med Res Opin*. 2004;20(9):1419-1428.
- Cohen SP, Raja SN. Chapter 29. Pain. In: Goldman L, Schafer AI, eds. *Goldman-Cecil Medicine*, 26e. Philadelphia, PA: Elsevier, Inc.; 2020. Available by subscription at: www.clinicalkey.com. Accessed February 18, 2021.
- Conaghan PG, O'Brien CM, Wilson M, et al. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomized trial. *Osteoarthritis Cartilage*. 2011;19(8):930-938.
- Zelaya C, Dahlhamer J, Lucas J, Connor EM, et al. Prevalence of chronic pain and high-impact chronic pain among adults — United States, 2019. *NCHS Data Brief*. 2020;(390): 1-8. Web site. <https://www.cdc.gov/nchs/data/databriefs/db390-H.pdf>. Accessed March 23, 2021.
- Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. *Crit Care Med*. 2018;46(9):e825-e873.
- Dolophine [package insert], Eatontown, NJ: West-Ward Pharmaceuticals; October 2019.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. *MMWR Recomm Rep* 2016;65:1-49. Web site. http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?_cid=rr6501e1_w#B1_down. Accessed February 18, 2021.
- Drugs@FDA: FDA approved drug products. Food and Drug Administration Web site. 2021. <https://www.accessdata.fda.gov/scripts/cder/daf/>. Accessed February 18, 2021.
- Duragesic [package insert], Titusville, NJ: Janssen Pharmaceutical, Inc.; October 2019.
- Exalgo [package insert], Webster Groves, MO: Mallinckrodt LLC.; June 2020.
- FDA Approved Risk Evaluation and Mitigation Strategies (REMS). Updated November 14, 2019. FDA Web site. <https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&REMS=17>. Accessed February 18, 2021.
- FDA Drug Safety Communication. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. 2019. FDA Web site. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes>. Accessed February 18, 2021.
- FDA Drug Safety Communication. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. 2020. FDA Web site. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain>. Accessed February 18, 2021.
- FDA Drug Safety Communication. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. 2017. FDA Web site. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications>. Accessed February 18, 2021.
- FDA Drug Safety Communication. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. August 2016b. FDA Web site. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or-cough-medicines-with-benzodiazepines-requires-its-strongest-warning>. Accessed February 18, 2021.
- FDA Drug Safety Communication. FDA warns about several safety issues with opioid pain medicines; requires label changes. March 2016a. FDA Web site. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-several-safety-issues-opioid-pain-medicines-requires>. Accessed February 18, 2021.

- FDA Industry Guidance. Guidance for Industry: Abuse-Deterrent Opioid – Evaluation and Labeling. 2015. FDA Web site. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling>. Accessed February 18, 2021.
- FDA Industry Guidance. Guidance for Industry: Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products. 2017. FDA Web site. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-evaluating-abuse-deterrence-generic-solid-oral-opioid-drug-products-guidance>. Accessed February 18, 2021.
- Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. *Br J Anaesth*. 2011;107(3):319-328.
- Finkel JC, Finley A, Greco C, et al. Transdermal fentanyl in the management of children with chronic severe pain. Results from an international study. *Cancer*. 2005;104(12):2847-2857.
- Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol*. 2015;14(2):162-173.
- Food and Drug Administration. Summary Review: OxyContin. 2015. FDA Web site. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022272Orig1s027SumR.pdf. Accessed February 18, 2021.
- Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy. *Neurology*. 2003;60(6):927-934.
- Gimbel J, Spierings EL, Katz N, Xiang Q, Tzannis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. *Pain*. 2016;157(11):2517-2526. Erratum in: *Pain*. 2017;158(2):366.
- Gordon A, Rashiq S, Moulin DE, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. *Pain Res Manag*. 2010a;15(3):169-178.
- Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. *Clin Ther*. 2010b;32(5):844-860.
- Hale ME, Moe D, Bond M, Gasior M, Malamut R. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. *Pain Manag*. 2016;6(5):497-508.
- Hale M, Tudor IC, Khanna S, et al. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, non inferiority analysis. *Clin Ther*. 2007;29(5):874-888.
- Hale M, Khan A, Kutch M, et al. Once-daily OROS hydromorphone ER compared to placebo in opioid-tolerant patients with chronic low back pain. *Curr Med Res Opin*. 2010;26(6):1505-1518.
- Hsu JR, Mir H, Wally MK, Seymour RB; Orthopedic Trauma Association Musculoskeletal Pain Task Force. Clinical practice guidelines for pain management in acute musculoskeletal injury. *J Orthop Trauma*. 2019;33(5):e158-e182. doi: 10.1097/BOT.0000000000001430.
- Hydromorphone extended-release [package insert], Lawrenceville, GA: XLCare Pharmaceuticals, Inc; October 2020.
- Hysingla ER [package insert], Stamford, CT: Purdue Pharmaceuticals, L.P.; October 2019.
- Kadian [package insert], Madison, NJ: Allergan USA, Inc.; October 2019.
- Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) vs prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group non inferiority study. *Clin Ther*. 2009;31(3):503-513.
- Katz N, Hale M, Morris D, et al. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. *Postgrad Med*. 2010;122(4):112-128.
- King SJ, Reid C, Forbes K, et al. A systematic review of oxycodone in the management of cancer pain. *Palliat Med*. 2011;25(5):454-470.
- Kivitz A, Ma C, Ahdieh H, et al. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. *Clin Ther*. 2006;38(3):352-364.
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Rheumatol*. 2020;72(2):220-233.
- Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. *JAMA*. 2018;319(9):872-882.
- Langford R, McKenna F, Ratcliffe S, et al. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis. *Arthritis Rheum*. 2006;54(6):1829-1837.
- Levorphanol [package insert], Philadelphia, PA: Lannett Company, Inc.; September 2020.
- Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. *Pain Physician*. 2017;20(2S):S3-S92.
- Medical Letter, Inc. Treatment guidelines from the Medical Letter: Drugs for Pain. 2013;11(128):31-42.
- Mesgarpour B, Griebler U, Glechner A, et al. Extended-release opioids in the management of cancer pain: a systematic review of efficacy and safety. *Eur J Pain*. 2014;18(5):605-616.
- Melilli G, Samolsky Dekel BG, Frenquelli C, et al. Transdermal opioids for cancer pain control in patients with renal impairment. *J Opioid Manag*. 2014;10(2):85-93.
- Mercadante S, Porzio G, Ferrera P, et al. Low doses of transdermal fentanyl in opioid-naïve patients with cancer pain. *Curr Med Res Opin*. 2010;26(12):2765-2768.
- Methadone oral solution [package insert], Eatontown, NJ: Hikma Pharmaceuticals USA Inc; July 2020.
- Methadose [package insert], Webster Groves, MO: Mallinckrodt Inc.; February 2020.
- Morley JS, Bridson J, Nash TP, et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. *Palliative Medicine*. 2003;17(7):576-587.
- Morphine sulfate extended release [package insert], Stamford, CT: Purdue Pharma L.P.; March 2021.
- MS Contin [package insert], Stamford, CT: Purdue Pharma L.P.; October 2019.

- Musclove SL, Bowers T, Vo H, et al. Long-acting morphine following hip or knee replacement: a randomized, double-blind and placebo-controlled trial (abstract). *Pain Res Manag.* 2012;17(2):83-88.
- National Academies of Science, Engineering, and Medicine (NASEM). Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. 2017. Web site. <http://nationalacademies.org/hmd/Reports/2017/pain-management-and-the-opioid-epidemic.aspx>. Accessed February 18, 2021.
- National Institute on Drug Abuse (NIDA). What is the Federal Government Doing to Combat the Opioid Abuse Epidemic? May 1, 2015. Web site. <http://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2015/what-federal-government-doing-to-combat-opioid-abuse-epidemic>. Accessed February 18, 2021.
- Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. *Cochrane Database Syst Rev.* 2017;2:CD003971.
- Nucynta ER [package insert], Stoughton, MA: Collegium Pharmaceutical, Inc.; October 2019.
- Office of Disease Prevention and Health Promotion. Pathways to Safer Opioid Use. Updated August 13, 2020. <http://health.gov/hcq/training-pathways.asp>. Accessed February 18, 2021.
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [database on the internet]. Silver Spring (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2021. <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed February 18, 2021.
- Overton HN, Hanna MN, Bruhn WE, Hutfless S, Bicket MC, Makary MA, for the Opioids after Surgery Workgroup. Opioid-prescribing guidelines for common surgical procedures: an expert panel consensus. *J Am Coll Surg.* 2018;227(4):411-418.
- OxyContin [package insert], Stamford, CT: Purdue Pharma L.P.; September 2020.
- Oxycodone extended-release [package insert], Brookhaven, NY: Amneal Pharmaceuticals of NY, LLC; January 2020.
- Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol.* 2016;34(27):3325-3345. doi: 10.1200/JCO.2016.68.5206.
- Park JH, Kim JH, Yun SC, et al. Evaluation of efficacy and safety of fentanyl transdermal patch (Duragesic D-TRANS) in chronic pain. *Acta Neurochir.* 2011;153(1):181-190.
- Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. *Palliat Med.* 2011;25(5):471-477.
- Qaseem A, McLean RM, O'Gurek D, Batur P, Lin K, Kansagara DL. Nonpharmacologic and pharmacologic management of acute pain from non-low back, musculoskeletal injuries in adults: a clinical guideline from the American College of Physicians and American Academy of Family Physicians. *Ann Intern Med.* 2020;173(9):739-748. doi: 10.7326/M19-3602.
- Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 2017;166(7):514-530.
- Quigley C. Hydromorphone for acute and chronic pain. *Cochrane Database Syst Rev.* 2002;(1):CD003447.
- Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. *Pain Med.* 2014;15(6):975-985.
- Rauck RL, Potts J, Xiang Q, et al. Efficacy and tolerability of buccal buprenorphine in opioid-naïve patients with moderate to severe chronic low back pain. *Postgrad Med.* 2016;128(1):1-11.
- Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. *Curr Med Res Opin.* 2011;27(1):151-162.
- Slatkin NE, Rhiner MI, Gould EM, et al. Long-term tolerability and effectiveness of oxycodone extended release in patients with cancer (abstract). *J Opioid Manag.* 2010;6(3):181-191.
- Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxycodone for the treatment of cancer pain: a pilot study. *Support Care Cancer.* 2005;13(1):57-65.
- Stewart M, Cibere J, Sayre EC, Kopec JA. Efficacy of commonly prescribed analgesics in the management of osteoarthritis: a systematic review and meta-analysis. *Rheumatol Int.* 2018;38(11):1985-1997. doi: 10.1007/s00296-018-4132-z.
- US Department of Health & Human Services (HHS). Naloxone: the opioid reversal drug that saves lives. December 2018. Web site. <https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf>. Accessed February 18, 2021.
- Watson CPN, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. *Pain.* 2003;105(1-2):71-78.
- Whittle SL, Richards BL, Husni E, et al. Opioid therapy for treating rheumatoid arthritis pain. *Cochrane Database Syst Rev.* 2011;(11):CD003113.
- Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain (review). *Cochrane Database Syst Rev.* 2016;4:CD003868. doi: 10.1002/14651858.CD003868.pub4.
- Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. *Pain Pract.* 2010;10(5):416-427.
- Xtampza ER [package insert], Cincinnati, OH: Patheon Pharmaceuticals; October 2019.
- Zohydro ER [package insert], Morristown, NJ: Currax Pharmaceuticals LLC; October 2019.

Publication date: April 1, 2021